Casi DeYoung
About Casi DeYoung
Casi DeYoung is Chief Business Officer at Shattuck Labs (STTK), serving since December 2019; she is 54 years old as of May 21, 2025, with a B.S. in Chemistry (Southwestern University) and an MBA from the McCombs School of Business at The University of Texas at Austin . Her career spans business development and corporate strategy roles across immuno-oncology and biotech; company performance context (for pay-performance alignment) shows revenues increased from 2022–2024 while EBITDA losses narrowed over the same period (table below) *.
Company performance (financial context):
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Revenues ($USD) | $652,000 | $1,657,000 | $5,721,000 |
| EBITDA ($USD) | -$98,156,000* | -$87,612,000* | -$76,516,000* |
Values retrieved from S&P Global.*
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| ImmuneSensor Therapeutics | Vice President & Chief Operating Officer | 2018–2019 | Led corporate strategy, start-up operations, IP, first IND filing and initiation of first-in-human Phase I trial |
| Mirna Therapeutics, Inc. | Chief Business Officer | 2014–2017 | Drove business development in oncology-focused biopharma |
| Reata Pharmaceuticals, Inc. | Vice President of Business Development | 2008–2013 | Led BD at clinical-stage biopharma |
| ODC Therapy, Inc. | Vice President of Business Development | 2005–2008 | Advanced BD in cancer immunotherapy |
| EMD Pharmaceuticals / Merck KGaA | Various roles | 2000–2005 | Commercial and operational roles at large-cap pharma |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| None disclosed | — | — | No public company board or external governance roles disclosed for DeYoung . |
Fixed Compensation
- Not disclosed for DeYoung in STTK’s EGC proxy NEO tables; the 2024–2025 proxy disclosures cover CEO, CFO, and CMO only, and do not present DeYoung’s base salary or bonus outcomes .
- Employment agreement exists (Dec 9, 2019) with an amendment (Mar 12, 2021), indicating formal terms are in place but not summarized in proxy; full content is incorporated by reference in the 2024 10-K exhibits .
Performance Compensation
- Company bonus framework for 2024: Compensation Committee set corporate performance goals (clinical milestones for SL‑172154, preclinical activities, manufacturing process improvements, and BD objectives); NEOs’ payouts were based on 60% corporate achievement plus individual performance evaluation .
- DeYoung’s individual metrics, weightings, targets, and payouts are not disclosed; only the corporate program design is described at company level .
Equity Ownership & Alignment
- Beneficial ownership: DeYoung is not itemized in the beneficial ownership tables; individual count is not disclosed in proxy (tables list NEOs/directors and group totals) .
- Section 16 compliance: One Form 4 for DeYoung (covering three transactions related to RSU/option grants) was filed late due to administrative error, indicating active equity grant participation and reporting oversight risk .
- Hedging/derivatives policy: Company prohibits short-term trading, short sales, publicly-traded options, and hedging transactions for insiders, strengthening alignment; pledging is not expressly addressed in disclosed policy text .
Employment Terms
- Agreement: Employment Agreement dated Dec 9, 2019 and Amendment dated Mar 12, 2021 are on file (incorporated by reference), confirming contractual governance of duties/compensation; specific severance/change-of-control terms for DeYoung are not summarized in proxy .
- Clawback: Company adopted a Rule 10D-1 clawback to recover excess incentive-based compensation over the prior three fiscal years upon a restatement .
- Insider trading controls: Formal insider trading policy in place with prohibitions on hedging/derivatives and timing practices for grants (no “spring loading” or grant timing tied to MNPI) .
Investment Implications
- Pay-for-performance transparency gap: As an EGC, STTK does not disclose DeYoung’s pay or award details; investors should request her salary, target bonus, equity mix, and ownership levels to assess alignment and retention risk .
- Insider activity signal: DeYoung’s late Form 4 (administrative error) signals reporting process risk; monitor future Forms 4 for selling pressure and vesting events, especially given RSU/option participation .
- Alignment policies are sound at company level (clawback, hedging prohibitions), but individual ownership/pledging status is unknown; obtain confirmations to rule out collateralization or guideline shortfalls .
- Company fundamentals improved (revenues up; EBITDA losses narrowing), supporting potential alignment narratives; however, without individual targets/weights, linkage of DeYoung’s variable pay to program execution (e.g., BD milestones, trial starts) cannot be verified *.
Values retrieved from S&P Global.*